Management of Graves' ophthalmopathy
Graves's ophthalmopathy, the commonest extrathyroidal manifestation of Graves' disease is an autoimmune disorder of the orbit. Restoration of thyroid dysfunction, lubricant eye drops and smoking cessation is important. Clinical activity and disease severity determine specific treatment. Referral to specialist centres is urgent in sight-threatning optic neuropathy. Intravenous methylprednisolone is first-line therapy for clinically active disease. Retrobulbar irradiation may help in persistant ocular muscle inflammation. Prompt orbital decompression is warranted for sight-threatning neuropathy not responding to high-dose methylprednisolone. Decompression is otherwise performed in the chronic phase, before possible eye-muscle and eyelid surgery. Rituximab is a promising immunomodulating drug for resistant clinically active cases.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:126 |
|---|---|
| Enthalten in: |
Duodecim; laaketieteellinen aikakauskirja - 126(2010), 20 vom: 20., Seite 2431-7 |
| Sprache: |
Finnisch |
|---|
| Weiterer Titel: |
Basedowin taudin silmäoireyhtymän hoito |
|---|
| Beteiligte Personen: |
Schalin-Jäntti, Camilla [VerfasserIn] |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 23.12.2010 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM204051479 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM204051479 | ||
| 003 | DE-627 | ||
| 005 | 20231223231309.0 | ||
| 007 | tu | ||
| 008 | 231223s2010 xx ||||| 00| ||fin c | ||
| 028 | 5 | 2 | |a pubmed24n0680.xml |
| 035 | |a (DE-627)NLM204051479 | ||
| 035 | |a (NLM)21125757 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fin | ||
| 100 | 1 | |a Schalin-Jäntti, Camilla |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of Graves' ophthalmopathy |
| 246 | 3 | 3 | |a Basedowin taudin silmäoireyhtymän hoito |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2010 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Graves's ophthalmopathy, the commonest extrathyroidal manifestation of Graves' disease is an autoimmune disorder of the orbit. Restoration of thyroid dysfunction, lubricant eye drops and smoking cessation is important. Clinical activity and disease severity determine specific treatment. Referral to specialist centres is urgent in sight-threatning optic neuropathy. Intravenous methylprednisolone is first-line therapy for clinically active disease. Retrobulbar irradiation may help in persistant ocular muscle inflammation. Prompt orbital decompression is warranted for sight-threatning neuropathy not responding to high-dose methylprednisolone. Decompression is otherwise performed in the chronic phase, before possible eye-muscle and eyelid surgery. Rituximab is a promising immunomodulating drug for resistant clinically active cases | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Murine-Derived |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Methylprednisolone |2 NLM | |
| 650 | 7 | |a X4W7ZR7023 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Duodecim; laaketieteellinen aikakauskirja |d 1945 |g 126(2010), 20 vom: 20., Seite 2431-7 |w (DE-627)NLM000016136 |x 0012-7183 |7 nnns |
| 773 | 1 | 8 | |g volume:126 |g year:2010 |g number:20 |g day:20 |g pages:2431-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 126 |j 2010 |e 20 |b 20 |h 2431-7 | ||